Autoimmune Myelofibrosis: Clinical Features, Course, and Outcome.

CONCLUSIONS: AIMF contributes to cytopenias in the subset of patients with various autoimmune disorders. The majority of patients with AIMF experience an improvement in cytopenias with immunosuppressive therapy. PMID: 28866671 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/28866671?dopt=Abstract

Source: Acta Haematologica - September 2, 2017 Category: Hematology Authors: Piatek CI, Vergara-Lluri ME, Pullarkat V, Siddiqi IN, O'Connell C, Brynes RK, Feinstein DI Tags: Acta Haematol Source Type: research

More News: Autoimmune Disease | Hematology | Myeloproliferative Disorders | Splenectomy | Study